A Peroxisome Proliferator-Activated Receptor γ-Retinoid X Receptor Heterodimer Physically Interacts with the Transcriptional Activator PAX6 to Inhibit Glucagon Gene Transcription

Ralph Krätzner, Florian Fröhlich, Katrin Lepler, Michaela Schröder, Katharina Röher, Corinna Dickel, Mladen V. Tzvetkov, Thomas Quentin, Elke Oetjen, and Willhart Kneapel


Received February 27, 2007; accepted October 25, 2007

ABSTRACT

The peptide hormone glucagon stimulates hepatic glucose output, and its levels in the blood are elevated in type 2 diabetes mellitus. The nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) has essential roles in glucose homeostasis, and thiazolidinedione PPARγ agonists are clinically important antidiabetic drugs. As part of their antidiabetic effect, thiazolidinediones such as rosiglitazone have been shown to inhibit glucagon gene transcription through binding to PPARγ and inhibition of the transcriptional activity of PAX6 that is required for cell-specific activation of the glucagon gene. However, how thiazolidinediones and PPARγ inhibit PAX6 activity at the glucagon promoter remained unknown. After transient transfection of a glucagon promoter-reporter fusion gene into a glucagon-producing pancreatic islet α-cell line, ligand-bound PPARγ was found in the present study to inhibit glucagon gene transcription also after deletion of its DNA-binding domain. Like PPARγ ligands, also retinoid X receptor (RXR) agonists inhibited glucagon gene transcription in a PPARγ-dependent manner. In glutathione transferase pull-down assays, the ligand-bound PPARγ-RXR heterodimer bound to the transcription domain of PAX6. This interaction depended on the presence of the ligand and RXR, but it was independent of the PPARγ DNA-binding domain. Chromatin immunoprecipitation experiments showed that PPARγ is recruited to the PAX6-binding proximal glucagon promoter. Taken together, the results of the present study support a model in which a ligand-bound PPARγ-RXR heterodimer physically interacts with promoter-bound PAX6 to inhibit glucagon gene transcription. These data define PAX6 as a novel physical target of PPARγ-RXR.

Peroxisome proliferator-activated receptor-γ (PPARγ) belongs to the superfamily of ligand-regulated nuclear hormone receptors (Desvergne and Wahli, 1999). It can be structurally subdivided into an amino-terminal, ligand-independent transactivation domain (AF-1) followed by a DNA-binding domain and a carboxyl-terminal, ligand-binding domain that contains a second, ligand-dependent transactivation surface (AF-2) (Desvergne and Wahli, 1999). PPARγ binds as a heterodimer with the 9-cis-retinoic acid (9cis-RA) receptor (RXR) to response elements (PPREs) in target genes to activate transcription. Upon ligand binding and depending on the tissue-specific cofactor environment, the PPARγ-RXR heterodimer recruits coactivators to stimulate promoter activity. This recruitment is dependent on ligand-induced allosteric alterations in the AF-2 helical domain (Nolte et al., 1998). In addition to transcriptional stimulation, PPARγ has been shown to be also capable of repression of gene transcription (Ricote et al., 1998; Schinner et al., 2002).

PPARγ is thought to be involved in a broad-range of cellular functions, including adipocyte differentiation, inflammation, blood pressure regulation, and apoptosis, and in chronic

ABBREVIATIONS: PPAR, peroxisome proliferator-activated receptor; AF, activation function; 9cis-RA, 9-cis-retinoic acid; RXR, retinoid X receptor; PPRE, peroxisome proliferator-activated receptor response element; PCR, polymerase chain reaction; GST, glutathione transferase; PMSF, phenylmethylsulfonyl fluoride; PAGE, polyacrylamide gel electrophoresis; GFP, green fluorescent protein; ChIP, chromatin immunoprecipitation; NF-κB, nuclear factor-κB; GW9662, 2-chloro-5-nitrobenzamide; BMS 649, 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-[1,3]dioxolan-2-yl]benzoic acid.
diseases such as obesity, atherosclerosis, metabolic syndrome, and cancer (Kersten et al., 2000). Of particular importance is its role in glucose homeostasis and type 2 diabetes mellitus (Kersten et al., 2000; Semple et al., 2006). Dominant-negative mutations in PPARγ are associated with insulin resistance and diabetes mellitus (Semple et al., 2006), suggesting that PPARγ agonists may be useful in the treatment of type 2 diabetes mellitus.

Besides naturally existing ligands such as 15-deoxy-Δ^{12,14}-prostaglandin J₂, several synthetic ligands of PPARγ as a new class of antidiabetic drugs have been synthesized, including the thiazolidinediones rosiglitazone and pioglitazone (Ikeda et al., 1990; Lehmann et al., 1995) In type 2 diabetes mellitus, thiazolidinediones lower blood glucose levels by binding to PPARγ, leading to a reduction in hepatic glucose output and a decrease in insulin resistance. PPARγ is expressed also in the α-cells of the pancreatic islets (Dubois et al., 2000), and we recently identified the glucagon gene as a novel thiazolidinedione target gene (Schinner et al., 2002).

The peptide hormone glucagon is synthesized in the α-cell of the endocrine pancreas (Unger and Orci, 1981). Glucagon stimulates glycolysis and gluconeogenesis and thereby increases hepatic glucose output. These actions of glucagon are opposite to those of insulin, the peptide hormone from pancreatic islet β-cells. Important in the coordination of the secretion of these two hormones is the direct inhibition by insulin of glucagon synthesis and secretion (Unger and Orci, 1981; Grzeskowiak et al., 2000). In insulin-resistant or deficient states, glucagon synthesis and secretion become disinhibited, leading to hyperglucagonemia that contributes to hyperglycemia in type 2 diabetes mellitus (Unger and Orci, 1981). Thiazolidinediones and PPARγ were shown to inhibit glucagon gene transcription and secretion (Schinner et al., 2002). This suggests that inhibition of glucagon gene expression may be among the multiple mechanisms through which thiazolidinediones improve glycemic control in diabetic subjects.

The pancreatic islet cell-specific enhancer sequence sequence motif within the glucagon gene promoter element G1 is required for PPARγ responsiveness (Schinner et al., 2002). This sequence motif does not bind PPARγ, but rather it binds the transcription factor PAX6 (St-Onge et al., 1997; Grzeskowiak et al., 2000), which is required for α-cell-specific activation of the glucagon gene (Grzeskowiak et al., 2000). PAX6 is composed of an amino-terminal paired domain followed by a linker region, a homeodomain, and a carboxy-terminal transactivation domain. The PAX6 transactivation domain recruits cofactors such as CREB-binding protein/p300, and it mediates the interaction with the general transcription machinery (Hussain and Habener, 1999). When the pancreatic islet cell-specific enhancer sequence motif within G1 was mutated into a GAL4 binding site, the expression of GAL4-PAX6 restored glucagon promoter activity and thiazolidinedione and PPARγ responsiveness (Schinner et al., 2002), suggesting that PPARγ in a ligand-dependent but DNA binding-independent manner inhibits PAX6 transcriptional activity on glucagon gene transcription. However, how PPARγ inhibits PAX6 transcriptional activity in molecular details remained unknown. The results of the present study suggest that thiazolidinediones and PPARγ inhibit glucagon gene transcription through a mechanism that involves a direct interaction of PPARγ with the PAX6 transactivation domain. In contrast to the glucocorticoid receptor, where transrepression is apparently mediated by glucocorticoid receptor monomers (Reichardt et al., 1998), transrepression of PAX6 seems to be conferred by PPARγ-RXR heterodimers. These data define PAX6 as a novel physical target of PPARγ-RXR, which may have implications beyond the regulation of glucagon gene transcription and blood glucose control.

**Materials and Methods**

**Plasmids.** The plasmids pcDNA3-PPARγ (Schinner et al., 2002), pGEX2T (GE Healthcare, Munich, Germany), pGST-PAX6(299-437) (Mikkola et al., 1999), and PPRE-Luc (Schinner et al., 2002) have been described previously. The plasmid pCMV-GFP-Ptpz was purchased from Canberra Packard (Dreieich, Germany). The expression vector pcDNA3-PPARγ was generated by EcoRI digestion of pSG5-RXRα (Heinlein et al., 1999) and cloning of the insert into EcoRI-digested pcDNA3. The plasmid pcDNA3-PPARγ was used as PCR template for the generation of all described PPARγ variants. PCR fragments coding for the described PPARγ variants were amplified using primer pairs introducing a 5’ KpnI and a 3’ XbaI site for cloning into pcDNA3. All constructs were confirmed by sequencing.

**In Vitro Transcription/Translation.** The TNT T7-coupled reticulocyte lysate system (L4610) was purchased from Promega (Madenmure, Germany). The reactions were carried out as recommended by the manufacturer.

**GST Pull-Down Assay.** The GST-PAX6(299-437) fusion protein and GST were expressed in Escherichia coli BL 21 and extracted using glutathione-agarose beads (Sigma-Aldrich, Munich, Germany). The proteins were stored bound to agarose beads on ice in phosphate-buffered saline buffer containing 1 mM dithiothreitol and 1 mM PMSF. To equalize amounts of GST-PAX6(299-437) and GST used in GST pull-down assays, the amounts were estimated by Coomassie Blue staining after SDS-PAGE. For the GST pull-down assays, the protein-covered beads were washed with NETN buffer containing 20 mM Tris/HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, pH 8.0, and 0.5% (v/v) Nonidet-P40 containing 1 mM dithiothreitol and 1 mM PMSF. For the binding step, 30 μl of GST-PAX6(299-437) or GST beads were added to 250 μl of NETN buffer and incubated with 7.5 μl of radioactively labeled in vitro-transcribed/translated protein at 4°C overnight. The beads were washed three times with 500 μl of ice-cold NETN buffer, and after the last washing step the supernatant was carefully removed and the pellet was boiled in 30 μl of 2× Laemmli sample buffer for 10 min. After SDS-PAGE, the radioactively labeled proteins were visualized using a Fuji Bio-Imaging Analyzer IPR 1800 (Fuji Film, Tokyo, Japan). Densitometry of band intensities was done using the program TINA version 2.09g (Santa Cruz Biotechnology, Inc., Heidelberg, Germany).

**Cell Culture and Transfection of DNA.** The glucagon-producing pancreatic islet α-cell line InR1-G (Schinner et al., 2002) was grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. Cells were trypsinized and transfected in suspension by the DEAE-dextran method (Schinner et al., 2002) with 2 μg of reporter gene plasmids, and, when indicated, 1 μg of expression vector per 6-cm dish. Cotransfections were carried out with a constant amount of DNA, which was maintained by adding pBlueScript (Stratagene, La Jolla, CA). In all experiments, 0.5 μg of cytomegalovirus-green fluorescent protein (GFP) (plasmid pCMV-GFPtpz) per 6-cm dish was cotransfected to check for transfection efficiency. Twenty-four hours after transfection, cells were incubated in RPMI 1640 medium containing 0.5% bovine serum albumin and antibiotics as described above. Cell extracts (Schinner et al., 2002) were prepared 48 h after transfection. The luciferase assay was performed as described previously (Schinner et al., 2002). Green fluorescent protein was measured in the cell extracts using the FluoroCount microplate fluorometer (PerkinElmer Life and Analytical Sciences, Waltham, MA).
Chromatin Immunoprecipitation and Quantitative PCR.
Two 16-cm dishes of confluent InR1-G9 cells transiently transfected with PPARγ-hemagglutinin were used for one ChIP experiment. For cross-linking, formaldehyde at a final concentration of 1% was added; after 10 min at room temperature, the reaction was stopped by adding glycine at a final concentration of 125 mM. After two washing steps in phosphate-buffered saline buffer, the cells were lysed on ice in 600 μl of lysis buffer [50 mM Tris/HCl, pH 8.1, 10 mM EDTA, 1% SDS (v/v), 1 mM PMSF, 1 mM leupeptin, 1 mM aprotinin, and 1 mM pepstatin] for 10 min. DNA was sonicated using three sets of 15 pulses at medium amplitude. After sonication lysates were precleared for 30 min at 4°C with 50 μl of equilibrated protein A/G agarose (Santa Cruz Biotechnology, Inc.). Ten micrograms of mouse anti-hemagglutinin antibody (Sigma-Aldrich) or IgG was added to 250 μl of the supernatant. The reaction was incubated overnight at 4°C. Then, 60 μl of protein A/G agarose slurry was added, and samples were incubated on a rotor for 2 h at 4°C. The precipitated complexes were washed twice in washing buffer 1 [20 mM Tris/HCl, pH 8.1, 150 mM NaCl, 2 mM EDTA, 0.1% SDS (v/v), and 1% Triton-X (v/v)], once in washing buffer 2 [20 mM Tris/HCl, pH 8.1, 500 mM NaCl, 2 mM EDTA, 0.1% SDS (v/v), and 1% Triton-X (v/v)], once in washing buffer 3 (20 mM Tris/HCl, pH 8.1, 250 mM LiCl, 1 mM EDTA, 1% Nonidet P-40 (v/v), 1% deoxylcholate), and once in TE buffer. The elution of DNA-protein complexes was performed in 10 mM Tris/HCl, pH 8.1, 1 mM EDTA, and 1% SDS. The crosslinks of DNA and protein were reversed by the addition of NaCl at a final concentration of 370 mM and by overnight incubation at 65°C. After proteinase K treatment, DNA was extracted using a PCR purification kit (QIAGEN, Hilden, Germany). The PCR was performed using a primer pair (hGlu-for 5′-GTGCCCTTCCATCTCACCACAC-3′ and hGlu-rev 5′-TCTGTCACAGGTTGCGTGC-3′) flanking the PAX6 binding site of the hamster glucagon gene promoter G1 element (annealing temperature 57°C, 25 cycles). Quantitative (real-time) PCR was performed using SYBR Green quantitative PCR core kit (Eurogentec, Seraing, Belgium) following the manufacturer’s instructions and using primers 5′-CTCC TTTCCA TTC CCA AAC-3′ and 5′-TCTG ACC AGG GTG CCG TGC-3′. The reaction was carried out in a 7900HT (Applied Biosystems, Weiterstadt, Germany) real-time PCR machine under the following conditions: 95°C for 10 min, 40 cycles of 94°C for 15 s, 62°C for 15 s, and 72°C for 1 min. The samples were measured in triplicates, and the average of the three threshold cycles (Ct) was used to calculate the relative amounts of template using the ΔCt method.

RNA Isolation, Reverse Transcription-PCR, and mRNA Quantification. RNA was extracted from InR1-G9 cells using TRIzol reagent (Sigma-Aldrich) according to standard procedures. RNA phase was purified using RNeasy kit columns (QIAGEN), and 1 μg of total RNA was transcribed into cDNA using random hexamer primers and SuperScript II reverse transcriptase according to the manufacturer’s protocol (Invitrogen, Paisley, UK). The mRNA expression was quantified by q SYBR Green Supermix in an iQ-Thermocycler (Bio-Rad Laboratories, Munich, Germany). The PCR was performed using an initial Taq-polymerase activating step at 95°C for 15 min followed by 30 cycles at 95°C, 30 s at 58°C, and 30 s at 72°C. After each run, a melting curve analysis was performed to ensure amplification of correct products. The mRNA expression of glucagon was normalized to the mRNA expression of glyceraldehyde-3-phosphate dehydrogenase.

Materials. BMS 649 was kindly provided by Hinrich Gronemeyer (Institut de Génétique et Biologie Moléculaire et Cellulaire, Strasbourg, France). Rosiglitazone was kindly provided by GlaxoSmithKline (Welwyn Garden City, Hertfordshire, UK). Luciferin was purchased from Promega, and 9-cis-retinoic acid and GW9662 were from Sigma-Aldrich, respectively.

**Results**

**PPARγ Inhibited Glucagon Gene Transcription Independently of Its DNA-Binding Domain.** Glucagon gene transcription was studied in the pancreatic islet α-cell line InR1-G9. Primary pancreatic islet α-cells express high levels of PPARγ (Dubois et al., 2000), and PPARγ agonists have been shown to inhibit glucagon synthesis and secretion in primary islets (Schinner et al., 2002). In contrast, InR1-G9 cells express low levels of PPARγ such that activation of a PPRE-linked reporter gene and inhibition of glucagon gene transcription by PPARγ agonists requires transfection of a PPARγ expression plasmid (Schinner et al., 2002). Furthermore, in this cell line in the presence of overexpressed PPARγ, treatment with 50 μM rosiglitazone decreased the mRNA level of endogenous glucagon by 37 ± 11.4% (P < 0.05; n = 4) (data not shown). This cell line, therefore, allows a direct assessment of the role of PPARγ and PPARγ variants in glucagon gene transcription. Glucagon gene transcription was studied in InR1-G9 cells using the reporter gene construct −350GluLuc (Schinner et al., 2002), which contains the rat glucagon gene promoter from −350 to +58 fused to the luciferase reporter gene. This glucagon promoter frag-
Fig. 2. The RXR agonists 9-cis-retinoic acid and BMS 649 inhibit glucagon gene transcription in a PPARγ-dependent manner. A, scheme of the reporter gene constructs −350GluLuc and PPRE-Luc. Control elements in the 5′-flanking region of the glucagon gene are indicated. B, luciferase reporter gene constructs −350GluLuc (left) and PPRE-Luc (right) were transfected into InR1-G9 cells with or without an expression vector encoding PPARγ. Cells were treated with increasing concentrations of 9-cis-retinoic for 24 h before harvest. Luciferase activity is expressed as percentage of the mean value, in each experiment, of the activity measured in the respective untreated controls. Values are means ± S.E.M. of three independent experiments, each done in duplicate. C, luciferase reporter gene constructs −350GluLuc and PPRE-Luc were transfected into InR1-G9 cells with an expression vector encoding PPARγ. Cells were treated with rosiglitazone (10 μM) or 9cis-RA (10 μM) for 24 h before harvest. Luciferase activity is expressed as
ment is sufficient to confer tissue-specific gene expression and regulation of gene transcription by cAMP-, calcium-, protein kinase C-, and insulin-induced signaling pathways (Unger and Orci, 1981; Knepel et al., 1990; Schwaniger et al., 1993a,b; Oetjen et al., 1994; Fürstenau et al., 1997; Grzeskowiak et al., 2000). It also confers responsiveness to thiazolidinediones and PPARγ (Schninner et al., 2002). To examine which domain of PPARγ is involved in the repression by PPARγ of glucagon gene transcription, we constructed the PPARγ variant PPARγ-(175-475)N. This variant lacks the DNA-binding domain, and it carries a carboxy-terminal extension of eight amino acids representing the nuclear localization sequence of the simian virus 40 large T antigen (PKKKRKVE) (Kalderon et al., 1984). To evaluate the effect of this carboxy-terminal nuclear localization signal on the inhibition of glucagon gene transcription by thiazolidinediones and PPARγ, we fused that sequence also to PPARγ full-length (construct PPARγ-(1-475)N). All PPARγ variants were cotransfected with −350Gluc into InR1-G9 cells. After treatment with rosiglitazone, all PPARγ variants inhibited glucagon gene transcription by 50 to 70% (Fig. 1). These data show that the ligand-binding domain of PPARγ is sufficient to inhibit glucagon gene transcription. These results thus support the previous conclusion that PPARγ does not bind to the glucagon promoter to inhibit glucagon gene transcription (Schninner et al., 2002); furthermore, they shown that transrepression by PPARγ is also independent of its DNA-binding domain.

**PPARγ Agonists Inhibited Glucagon Gene Transcription in a PPARγ-Dependent Manner.** PPARγ activates gene transcription by binding as a heterodimer with RXR to PPREs in the promoter region of target genes (Desvergne and Wahli, 1999). PPARγ-RXR is a permissive heterodimer, the transcriptional activity of which can be activated by both PPARγ agonists and RXR agonists (Kliwer et al., 1992). To examine whether RXR is involved in the repression of glucagon gene transcription by thiazolidinediones and PPARγ, the effect of RXR agonists on glucagon gene transcription was studied. In the absence of PPARγ, the RXR agonist 9-cis-retinoic acid at concentrations up to 1 μM had no effect on glucagon gene transcription (Fig. 2B, left). However, in the presence of PPARγ, 9-cis-retinoic acid inhibited glucagon gene transcription (Fig. 2B, left) at concentrations that also activated a PPRE-linked reporter gene (Fig. 2B, right). The activation by 9-cis-retinoic acid of PPRE-Luc in the presence of PPARγ but without cotransfection of an RXR expression plasmid indicates that InR1-G9 cells express sufficiently high levels of endogenous RXR, as has been shown previously (Schninner et al., 2002). The maximum inhibition of glucagon gene transcription by the RXR agonist 9-cis-retinoic acid in the presence of PPARγ (by approximately 40%) (Fig. 2C, left) was somewhat less than the maximum inhibition by the PPARγ agonist rosiglitazone (inhibition by approximately 60%) (Fig. 2C, left). Likewise, the activation of PPRE-Luc by 9-cis-retinoic acid was lower than that by rosiglitazone (Fig. 2C, right). 9-cis-Retinoic acid acts as an agonist at the RXR and retinoic acid receptor (Heyman et al., 1992; Boehm et al., 1994). Although only RXR, but not retinoic acid receptor, heterodimerizes with PPARγ (Desvergne and Wahli, 1999), the effect of a specific RXR agonist, BMS 649 (Mukherjee et al., 1997), was studied. Like 9-cis-retinoic acid, also BMS 649 inhibited glucagon gene transcription and it activated a PPRE-linked reporter gene in the presence of PPARγ (Fig. 2D). Increasing concentrations of the PPARγ antagonist GW9662 (Seargent et al., 2004) stimulated glucagon gene transcription (Fig. 2E). These data show that, in addition to the thiazolidinedione PPARγ agonists, RXR agonists also inhibit glucagon gene transcription in a PPARγ-dependent manner, consistent with the view that inhibition of glucagon gene transcription is mediated by a PPARγ-RXR heterodimer.

**A Direct Protein-Protein Interaction between PPARγ and the PAX6 Transactivation Domain Depending on the Presence of RXR and the Thiazolidinedione Rosiglitazone Was Revealed by GST Pull-Down Assays.** To test whether the inhibition of glucagon gene transcription by thiazolidinediones and PPARγ may involve a physical interaction between PPARγ and PAX6, the GST pull-down assay was used. The PAX6 transactivation domain was fused to GST, expressed in E. coli, immobilized on glutathione-coated beads, and incubated with PPARγ, RXRα, or both, that had been radioactively labeled with [35S]methionine by in vitro transcription/translation. After the binding reaction, the agarose beads were washed and retained proteins were analyzed by SDS polyacrylamide gel electrophoresis. Compared with GST, which served as a negative control, the GST-PAX6 transactivation domain retained the cotranscribed/cotranslated PPARγ-RXXR heterodimer (Fig. 3, A, C, and D), whereas PPARγ alone or RXRα alone were not sufficiently retained (Fig. 3A). The interaction between the PAX6 transactivation domain and the PPARγ-RXXR heterodimer was further enhanced by the PPARγ ligand rosiglitazone (Fig. 3B). In addition, in the presence of rosiglitazone the interaction depended on RXRα because the signal intensity markedly decreased when the PAX6 transactivation domain was incubated with PPARγ alone (Fig. 3C, compare first lane with third lane). In addition, the PPARγ antagonist GW9662 reduced the interaction between the PAX6 transactivation domain and PPARγ-(245-475)-RXRα heterodimer (Fig. 3D). In contrast, the ligand-induced interaction did not depend on the PPARγ-DNA-binding domain, because upon cotranscription/cotranslation, the PPARγ-(245-475)-RXRα heterodimer bound to the PAX6 transactivation domain (Fig. 3D).

**Recruitment of PPARγ to the Glucagon Gene Promoter Was Revealed by Chromatin Immunoprecipitation.** If the PPARγ-RXR heterodimer interacts with PAX6 also in vivo, PPARγ should be recruited through PAX6 to the
glucagon promoter, in spite of the fact that PPARγ does not bind to glucagon promoter sequences. This was studied by chromatin immunoprecipitation. After PPARγ transfection and rosiglitazone treatment of InR1-G9 cells, chromatin-bound proteins were cross-linked by formaldehyde. After cell lysis and DNA fragmentation by sonication, PPARγ-bound DNA was immunoprecipitated and amplified by PCR using a primer pair flanking the PAX6 binding site in the glucagon promoter G1 element. Compared with an immunoprecipitation using unspecific immunoglobulins, serving as a negative control, antibodies against PPARγ precipitated a glucagon promoter fragment that includes the G1 PAX6 binding site (Fig. 4A), indicating recruitment of PPARγ to the glucagon gene promoter in vivo. To investigate whether rosiglitazone enhanced the recruitment of PPARγ to the glucagon gene promoter in vivo, the rat glucagon promoter and the expression for PPARγ were cotransfected, cells were treated with rosiglitazone and a ChIP assay followed by quantitative PCR was performed. In the presence of the PPARγ agonist, the recruitment of PPARγ to the glucagon promoter was 5.8-fold enhanced (Fig. 4B). In addition, rosiglitazone enhanced the recruitment of PPARγ to the genomic (hamster) glucagon promoter 5.9- and 1.9-fold, respectively (data not shown), indicating that rosiglitazone stimulated the recruitment of PPARγ to the glucagon gene promoter in vivo.

Discussion

Thiazolidinediones are a new class of oral antidiabetic drugs. Through binding to PPARγ, they lower hepatic glucose
output and reduce insulin resistance in type 2 diabetes mellitus, emphasizing the pivotal role of PPARγ in blood glucose control (Semple et al., 2006). As part of their antidiabetic effect, thiazolidinediones have been shown to inhibit glucagon gene transcription by inhibiting the transcriptional activity of PAX6 (Schinner et al., 2002), which is required for α-cell-specific activation of the glucagon gene (Grzeskowiak et al., 2000). The present study now suggests a mechanism through which thiazolidinediones and PPARγ inhibit PAX6 activity and thus glucagon gene transcription in pancreatic islet α-cells. The results of the present study are consistent with a model in which a ligand-bound PPARγ-RXR heterodimer physically interacts with promoter-bound PAX6 (Fig. 5). This interaction is independent of the PPARγ DNA-binding domain. These data thereby define PAX6 as a novel physical target of PPARγ.

It has been shown previously that PPARγ inhibits glucagon gene transcription without binding to the glucagon promoter (Schinner et al., 2002). This view is further supported by the finding in the present study that PPARγ inhibits glucagon gene transcription also after deletion of its DNA-binding domain. The inhibition by PPARγ does, however, seem to depend on heterodimerization with RXR. PPARγ and RXR are known to heterodimerize in solution through their ligand-binding domains (Kliewer et al., 1992; Gampe et al., 2000). An intriguing aspect of RXR heterodimers is that some are permissive for activation by RXR ligands, whereas others are not. The PPARγ-RXR heterodimer falls into the permissive category of RXR heterodimers (Kliewer et al., 1992). Because of the permissive nature of the PPARγ-RXR heterodimer, RXR agonists have many of the same effects as do PPARγ agonists, and they have been shown to possess antidiabetic activity in mouse models of type 2 diabetes mellitus (Mukherjee et al., 1997). The asymmetric interactions between the AF-2 of PPARγ and helices 7 and 10 of RXRα, as revealed by the crystal structure of the PPARγ-RXRα ligand-binding domains (Gampe et al., 2000), suggest a structural basis for permissiveness. The net effect of these interactions may be the stabilization of the PPARγ AF-2 helix in an active conformation even in the absence of a bound PPARγ agonist (Gampe et al., 2000). Because in the present study RXR agonists inhibited glucagon gene transcription in a strictly PPARγ-dependent manner, the results indicate that a PPARγ-RXR heterodimer confers inhibition of glucagon gene transcription. They thereby suggest that also the inhibition by thiazolidinediones is mediated by PPARγ-RXR heterodimers.

Several distinct underlying mechanisms for transrepression by nuclear receptors have been described. Nuclear receptors were shown to inhibit activator protein-1-mediated transcription of target genes by competition for limiting amounts of the coactivators CREB-binding protein/p300 (Kamei et al., 1996). Alternatively, nuclear receptors may interfere with signaling pathways. For example, glucocorticoids induce the disassembly of c-Jun NH₂-terminal kinase from mitogen-activated protein kinase kinase 7 by promoting its association with the glucocorticoid receptor, leading to the inhibition of c-Jun NH₂-terminal kinase-dependent transcription factors and their target genes (Bruna et al., 2003). A third mechanism of transrepression is through direct interaction with transcription factors, as exemplified by the interaction between the glucocorticoid receptor and the p65 subunit of NF-κB (Garside et al., 2004). Although the data of the present study do not exclude additional mechanisms, they strongly suggest that the mechanism through which PPARγ inhibits PAX6 activity and thus glucagon gene transcription involves a protein-protein interaction with PAX6. The ligand-bound PPARγ-RXR heterodimer was found in the GST pull-down assay to bind to the transactivation domain of PAX6. This binding depended on the presence of rosiglitazone and RXR, but it was independent of the PPARγ DNA-binding domain.
binding domain. The requirements for the binding of PPARγ to PAX6 are thus similar to those for the inhibition of glucagon gene transcription by PPARγ (Schinner et al., 2002; this study), suggesting that this binding may underlie the repression of transcription. The chromatin immunoprecipitation assay showed that PPARγ becomes recruited to the PAX6-responsive region of the proximal glucagon promoter, although PPARγ does not bind to these sequences (Schinner et al., 2002), indicating that PPARγ associates with PAX6 also in vivo. Furthermore, that PPARγ associates with promoter-bound PAX6. Taken together, the results of the present study thus support a model in which a ligand-bound PPARγ-RXR heterodimer physically interacts with promoter-bound PAX6 to inhibit glucagon gene transcription (Fig. 5).

This suggested model contrasts with defined mechanisms of interaction of nuclear receptors with promoter-bound transcription factors. Thus, NF-κB activity is inhibited by binding of the p65 subunit of NF-κB to the DNA-binding domain of the glucocorticoid receptor (Chung et al., 2000; Nissen and Yamamoto, 2000), whereas PPARγ interacts with PAX6 and inhibits glucagon gene transcription independently of its DNA-binding domain. Furthermore, although PPARγ acts at PAX6 and the glucagon promoter as a PPARγ-RXR heterodimer, transrepression by the glucocorticoid receptor is apparently mediated by glucocorticoid receptor monomers (Reichardt et al., 1998). In fact, transactivation-defective mutants of the glucocorticoid receptor, which cannot dimerize or bind DNA, are fully competent in transrepression (Reichardt et al., 1998). Likewise, PPARγ has been shown to bind the p65 subunit of NF-κB as a monomer (i.e., in the absence of RXR) and in a ligand-independent manner (Chung et al., 2000). This interaction seems to be stabilized at the mouse inducible nitric-oxide synthase promoter in the RAW264.7 macrophage cell line by multiple cofactors (Pascual et al., 2005). This multiplicity of mechanisms indicates that distinct interaction surfaces are used by nuclear receptors depending on both the specific nuclear receptor, and, for a given receptor, the target transcription factor. The inhibition by the PPARγ-RXR heterodimer of transforming growth factor-β1 gene transcription in the L929 fibroblast cell line, in contrast, is not through transrepression but it seems to be indirectly mediated (Lee et al., 2006). PPARγ-RXR has been shown to bind a PPRE in the promoter of the gene encoding the 3′-phosphatase phosphatase and tensin homolog deleted from chromosome 10 and to induce phosphatase and tensin homolog deleted from chromosome 10 expression, which through inhibition of phosphoinositide 3-kinase leads to a diminished phosphorylation and thus inactivation of the transcription factor Zif9 that is required for transforming growth factor-β1 gene transcription (Lee et al., 2006).

The present study identifies PAX6 as a novel physical target of PPARγ-RXR. This may have implications beyond the regulation of glucagon gene transcription in pancreatic islet α-cells. PPARγ and PAX6 are coexpressed also in pancreatic islet β-cells (Callaerts et al., 1997; St-Onge et al., 1997; Dubois et al., 2000). PAX6 expression in the pancreas is initiated in the pancreatic progenitors, concomitant with the onset of hormone expression, after which the expression persists in all endocrine cells throughout development and in the adult pancreas (Callaerts et al., 1997; St-Onge et al., 1997). The phenotype of PAX6 mutants suggests a specific role for this gene in the differentiation of α-cells and for the normal numbers and hormone expression of other endocrine cell types, including β-cells. In contrast, the activation of PPARγ has been shown to reduce the proliferation of β-cells (Rosen et al., 2003) in addition to inducing the expression of glucokinase (Kim et al., 2002) and the glucose transporter GLUT2 in β-cells (Kim et al., 2000). An involvement of PAX6 in these actions remains to be examined. A PAX6-PPARγ-RXR interaction could have implications also beyond blood glucose control by thiazolidinediones oral antidiabetic drugs in type 2 diabetes mellitus. The transcription factor PAX6 is highly conserved in evolution, and it is considered to be a master gene for the development of the eye in species from Drosophila melanogaster to human (Callaerts et al., 1997). It plays an important role also in the development of the nose and brain (Callaerts et al., 1997). In addition to the pancreas, PAX6 is accordingly expressed in the eye and nasal epithelium. It is also expressed in the developing and adult brain (Callaerts et al., 1997) where its expression exhibits some temporal and spatial overlap with the expression of PPARγ (Zhao et al., 2006), raising the possibility of a PPARγ-PAX6 interaction also in the brain. Noteworthy, the number of PAX6-expressing neurons in the brain is increased by cerebral ischemia, when the activation of PPARγ is known to promote neuroprotection (Zhao et al., 2006).

Acknowledgments

BMS 649 was kindly provided by Hinrich Grönemeyer. We thank Stephan Herzig (Heidelberg, Germany) for advice on the chromatin immunoprecipitation assay.

References


Adress correspondence to: Dr. Elke Oetjen, Molecular Pharmacology, University of Goettingen, Robert-Koch-Str. 40, 37099 Goettingen, Germany. E-mail: eoetjen@med.uni-goettingen.de